Brief: Alx Oncology Presents First Evorpacept Combination Data With An Antibody-Drug Conjugate From Phase 1 Aspen-07 Clinical Trial In Patients With Advanced Bladder Cancer
02/06/2024 15:03
June 2 (Reuters) - ALX Oncology Holdings Inc ALXO.O :
* ALX ONCOLOGY PRESENTS FIRST EVORPACEPT COMBINATION DATA
WITH AN
ANTIBODY-DRUG CONJUGATE FROM PHASE 1 ASPEN-07 CLINICAL TRIAL IN
PATIENTS WITH ADVANCED BLADDER CANCER
Source text for Eikon: ID:nGNX848GLX
Further company coverage: ALXO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on ALX Oncology Holdings
See all newsALX Oncology Holdings Inc reports results for the quarter ended June 30 - Earnings Summary
ALX Oncology Holdings Inc expected to post a loss of 15 cents a share - Earnings Preview
ALX Oncology Q2 net loss narrows on lower R&D costs
Brief: ALX Oncology Q2 Basic EPS USD -0.13
Brief: Alx Oncology Holdings - Enters Loan And Security Agreement With HSBC Ventures On June 25, 2026 - SEC Filing